|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2008-2-25
|
|
pubmed:abstractText |
The type I interferon (IFN) pathway is activated in many patients with systemic lupus erythematosus (SLE), and high serum levels of IFN are associated with anti-SSA/Ro autoantibodies. To investigate the clinical features associated with type I IFN production in vivo, we compared serum IFN activity in individuals with anti-SSA/Ro antibodies who were asymptomatic with that in individuals with clinical manifestations of SLE or Sjögren's syndrome (SS).
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/18240214-12006334,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18240214-12642603,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18240214-15188363,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18240214-15593221,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18240214-15818675,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18240214-15880830,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18240214-16477017,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18240214-16736505,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18240214-17417641,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18240214-17581626,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18240214-18050196,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18240214-2449306,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18240214-7138600,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18240214-9626848
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0004-3591
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
58
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
541-6
|
|
pubmed:dateRevised |
2011-6-9
|
|
pubmed:meshHeading |
pubmed-meshheading:18240214-Adult,
pubmed-meshheading:18240214-Antibodies, Antinuclear,
pubmed-meshheading:18240214-Female,
pubmed-meshheading:18240214-Follow-Up Studies,
pubmed-meshheading:18240214-Humans,
pubmed-meshheading:18240214-Infant, Newborn,
pubmed-meshheading:18240214-Infant, Newborn, Diseases,
pubmed-meshheading:18240214-Interferon Type I,
pubmed-meshheading:18240214-Longitudinal Studies,
pubmed-meshheading:18240214-Lupus Erythematosus, Systemic,
pubmed-meshheading:18240214-Pregnancy,
pubmed-meshheading:18240214-Pregnancy Complications,
pubmed-meshheading:18240214-Registries,
pubmed-meshheading:18240214-Sjogren's Syndrome
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Serum type I interferon activity is dependent on maternal diagnosis in anti-SSA/Ro-positive mothers of children with neonatal lupus.
|
|
pubmed:affiliation |
University of Chicago, Section of Rheumatology, Chicago, Illinois 60637, USA. tniewold@medicine.bsd.uchicago.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|
